Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05581173 · ClinicalTrials.gov registry record
Self-Assembling Matrix Forming Gel to Prevent Stricture Formation
A clinical trial, sponsored by AdventHealth.
- Completed
- Registry status
- 41
- Enrollment target
NCT05581173: Completed study, sponsored by AdventHealth.
NCT05581173 is a clinical trial that has completed, run by AdventHealth. The registered enrollment target is 41 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05581173 has completed, sponsored by AdventHealth.
- COMPLETED
- Registry status
- 41 participants
- Enrollment target
Study Summary
The study is designed as a multicenter prospective registry study evaluating the efficacy of the self-assembling peptide in the prevention of stricture formation after endoscopic resection as part of standard medical care. No experimental interventions will be performed.
Primary Outcome
Esophageal stricture will be defined as symptoms of dysphagia with concomitant endoscopy showing an inability to pass a standard endoscope due to luminal narrowing at the site of the resection scar.
Interventions
- DEVICE Purastat SAP gel application
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2022-09-19 |
| Est. Completion | 2025-01-23 |
What the finished NCT05581173 record still lists
NCT05581173 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 41 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Purastat SAP gel application is the first listed.
NCT05581173 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05581173 about?
NCT05581173 is a clinical study titled "Self-Assembling Matrix Forming Gel to Prevent Stricture Formation". The study is designed as a multicenter prospective registry study evaluating the efficacy of the self-assembling peptide in the prevention of stricture formation after endoscopic resection as part of standard medical care. No experimental interventions will be performed.
What is the current status of trial NCT05581173?
This trial is currently completed. The enrollment target is 41 participants. The study started on 2022-09-19. Estimated completion is 2025-01-23.
What interventions are being tested in trial NCT05581173?
The interventions under investigation include: Purastat SAP gel application (DEVICE).
Who is sponsoring clinical trial NCT05581173?
This trial is sponsored by AdventHealth, which has 95 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03449238 · 41 participants · Phase 1
Pembrolizumab And Stereotactic Radiosurgery (Srs) Of Selected Brain Metastases In Breast Cancer Patients
- NCT03900793 · 41 participants · Phase 1
Losartan + Sunitinib in Treatment of Osteosarcoma
- NCT04082520 · 41 participants · Phase 2
Lutathera for the Treatment of Inoperable, Progressive Meningioma After External Beam Radiation Therapy
- NCT04220190 · 41 participants · Phase 2
RAPA-501 Therapy for ALS
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI